drugset / Trial / NCT07634471
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
RandomizedParallel-groupSingle-blindTreatment
Summary
Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy)
Timeline
- Start
- 2026-06-22
- Primary completion
- 2032-07-23
- Completion
- 2035-07-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-1045 | Other / unclassified | 2 mg | Intravenous |
| Subject | MK-1045 | Other / unclassified | 90 mg | Intravenous |
| Background | Bendamustine | Small molecule | 90 mg/m2 | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | Intravenous |
| Background | Doxorubicin | Other / unclassified | 50 mg/m2 | Intravenous |
| Background | Prednisolone | Other / unclassified | 40 mg | — |
| Background | Prednisolone | Other / unclassified | 100 mg/m2 | — |
| Background | Prednisone | Other / unclassified | 40 mg | — |
| Background | Prednisone | Other / unclassified | 100 mg/m2 | — |
| Background | Riabni | Unknown | 375 mg/m2 | Intravenous |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Background | Vincristine | Small molecule | 1.4 mg/m2 | Intravenous |